Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

AmSurg to purchase NSC's assets for $135 million in cash

Christopher A. Holden, President and Chief Executive Officer of AmSurg Corp., today announced that AmSurg and National Surgical Care (NSC) have signed a revised definitive agreement under which AmSurg will purchase substantially all of NSC's assets for $135 million in cash.

24 Aug 2011

Researchers discover expression of IL-37 that protects mice from colitis

Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.

24 Aug 2011

New advances in genomics, molecular diagnostics to be showcased at CAP 2011 meeting

The latest developments in molecular diagnostics, personalized medicine, and genetics testing will be featured topics when more than 1,000 pathologists gather at the Gaylord Texan on September 11 – 14 for the annual scientific meeting of the College of American Pathologists.

24 Aug 2011

Hospital acquired Clostridium difficile bug defense system identified

American researchers have discovered the process by which the cells in the gut fight off toxins produced by a hospital bug - Clostridium difficile. Writing in Nature Medicine, they showed how a chemical - GSNO - deactivated a toxin from Clostridium difficile which causes inflammation and diarrhea. They hope to use their findings to develop a treatment for C. difficile.

23 Aug 2011

Stem cells of oral mucosa stay young, says Tel Aviv University researcher

While highly potent embryonic stem cells are often the subject of ethical and safety controversy, adult-derived stem cells have other problems. As we age, our stem cells are less pliant and less able to transform into the stem cells that science needs to find breakthrough treatments for disease.

23 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

New CDI therapeutic approach may offer treatment for other bacterial diseases

Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.

22 Aug 2011

Quanterix's ELISA precisely measures low abundance cytokines in Crohn's disease

Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease.

20 Aug 2011

National analysis identifies Columbus as one of the Hypertension Hot Spots in the U.S.

A national analysis conducted by Sperling's BestPlaces and sponsored by Takeda Pharmaceuticals North America, Inc., identified Columbus, Ohio, as one of the nation's Hypertension Hot Spots, or cities that have hypertension risk factors and complications.

18 Aug 2011

Fresh food for years with newly discovered natural preservative

Scientists have discovered a natural preservative capable of destroying a whole class of bacteria, including E.coli and listeria and now food can be made to remain fresh and last for years. There would also be no need to refrigerate produce treated with the preservative, called, bisin, which is produced by harmless bacteria.

15 Aug 2011

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

12 Aug 2011

Radiofrequency ablation safe and effective for treatment of dysplastic Barrett's esophagus

Radiofrequency ablation (RFA) is a safe and effective option for the treatment of dysplastic Barrett's esophagus that attains lasting response, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. Progression of disease, which can precede cancer, was rare in patients who underwent RFA treatment, and there was no procedure- or cancer-related mortality.

12 Aug 2011

Scientists identify 29 new genetic variants linked to multiple sclerosis

Scientists have identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of a very debilitating neurological disease. Many of the genes -implicated in the study are relevant to the immune system, shedding light onto the immunological pathways that underlie the development of multiple sclerosis.

11 Aug 2011

57 genes associated with multiple sclerosis

An international research team has found nearly 30 genetic risk factors that predispose to developing multiple sclerosis. It brings to more than 50 the total number of genetic clues to the disease. The research, published in Nature, will help identify risk factors and perhaps future treatments or even a cure, hopes the MS Society.

11 Aug 2011

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.

11 Aug 2011

First bioengineered anal sphincter for treatment of fecal and urinary incontinence

Researchers have built the first functional anal sphincters in the laboratory, suggesting a potential future treatment for both fecal and urinary incontinence. Made from muscle and nerve cells, the sphincters developed a blood supply and maintained function when implanted in mice.

10 Aug 2011

Common culinary spice derivative could treat tendinitis

A derivative of a common culinary spice found in Indian curries could offer a new treatment hope for sufferers of the painful condition tendinitis, an international team of researchers has shown.

9 Aug 2011

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

Study helps clarify definition of gastroesophageal reflux disease

Modifying stomach acid levels may not be enough to treat symptoms in neonates suspected of having gastroesophageal reflux disease. According to a study from Nationwide Children's Hospital, this is the first study to classify reflux and its associated symptoms in neonates based on how and what is refluxed.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011